Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Bend Medical Clinic
1294
mi
from
Bend, OR
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Bend Medical Clinic
1294
mi
from
Bend, OR
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Providence Portland Medical Center
1383
mi
from
Portland, OR
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Providence Portland Medical Center
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
University of Tennessee Medical Center
779
mi
from
Knoxville, TN
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Tennessee Medical Center
779
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Center for Clinical Studies
588
mi
from
Webster, TX
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Center for Clinical Studies
588
mi
from
Webster, TX
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Intermountain Medical Center
779
mi
from
Murray, UT
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Intermountain Medical Center
779
mi
from
Murray, UT
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Huntsman Cancer Institute at University of Utah
777
mi
from
Salt Lake City, UT
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Huntsman Cancer Institute at University of Utah
777
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
University of Virginia Hospital
1053
mi
from
Charlottesville, VA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Virginia Hospital
1053
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Virginia Mason Medical Center
1410
mi
from
Seattle, WA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Virginia Mason Medical Center
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Multicare Institute for Research and Innovation
1408
mi
from
Tacoma, WA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Multicare Institute for Research and Innovation
1408
mi
from
Tacoma, WA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Mount Sinai School of Medicine
1290
mi
from
New York, NY
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Mount Sinai School of Medicine
1290
mi
from
New York, NY
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Beverly Hills Cancer Center
1175
mi
from
Beverly Hills, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Beverly Hills Cancer Center
1175
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
UCLA Hematology/Oncology Clinic
1179
mi
from
Los Angeles, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
UCLA Hematology/Oncology Clinic
1179
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
IMMUNOe Research Centers
400
mi
from
Centennial, CO
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
IMMUNOe Research Centers
400
mi
from
Centennial, CO
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
IMMUNOe Research Centers
424
mi
from
Longmont, CO
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
IMMUNOe Research Centers
424
mi
from
Longmont, CO
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Integrity Clinical Research, LLC
1313
mi
from
Doral, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Integrity Clinical Research, LLC
1313
mi
from
Doral, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
21st Century Oncology
1065
mi
from
Jacksonville, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
21st Century Oncology
1065
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Olympian Clinical Research
1115
mi
from
Tampa, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Olympian Clinical Research
1115
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Baptist Health Lexington
724
mi
from
Lexington, KY
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Baptist Health Lexington
724
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
John Theurer Cancer Center/ Hackensack Medical Center
1284
mi
from
Hackensack, NJ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
John Theurer Cancer Center/ Hackensack Medical Center
1284
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Rutgers Cancer Institute of NJ
1263
mi
from
New Brunswick, NJ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Rutgers Cancer Institute of NJ
1263
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Fairview Hospital (Cleveland Clinic)
887
mi
from
Cleveland, OH
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Fairview Hospital (Cleveland Clinic)
887
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Cleveland Clinic Foundation
898
mi
from
Cleveland, OH
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Cleveland Clinic Foundation
898
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Premier Health Partners Clinical Trials Research Alliance
752
mi
from
Dayton, OH
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Premier Health Partners Clinical Trials Research Alliance
752
mi
from
Dayton, OH
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Independence Family Health Center (Cleveland Clinic)
895
mi
from
Independence, OH
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Independence Family Health Center (Cleveland Clinic)
895
mi
from
Independence, OH
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Hillcrest Hospital - Cleveland Clinic
907
mi
from
Mayfield Heights, OH
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Hillcrest Hospital - Cleveland Clinic
907
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Oregon Health and Science University
1383
mi
from
Portland, OR
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Oregon Health and Science University
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Thomas Jefferson Medical Oncology
1225
mi
from
Philadelphia, PA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Thomas Jefferson Medical Oncology
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
McGlinn Cancer Institute, Reading Hospital
1184
mi
from
West Reading, PA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
McGlinn Cancer Institute, Reading Hospital
1184
mi
from
West Reading, PA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
The West Clinic, P.C. d/b/a West Cancer Center
599
mi
from
Germantown, TN
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
The West Clinic, P.C. d/b/a West Cancer Center
599
mi
from
Germantown, TN
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Baylor Research Institute
347
mi
from
Dallas, TX
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Baylor Research Institute
347
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Cancer Solutions
341
mi
from
Dallas, TX
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Cancer Solutions
341
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Center for Clinical Studies Houston B
571
mi
from
Houston, TX
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Center for Clinical Studies Houston B
571
mi
from
Houston, TX
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Inova Melanoma and Skin Cancer Center
1116
mi
from
Fairfax, VA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Inova Melanoma and Skin Cancer Center
1116
mi
from
Fairfax, VA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
BCCA Vancouver Island Cancer Center
1473
mi
from
Victoria,
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
BCCA Vancouver Island Cancer Center
1473
mi
from
Victoria,
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
The Melanoma Center at the Washington Cancer Institute
1128
mi
from
Washington, D.C.,
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
The Melanoma Center at the Washington Cancer Institute
1128
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Southern Illinois University School of Medicine
462
mi
from
Springfield, IL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Southern Illinois University School of Medicine
462
mi
from
Springfield, IL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
MediSearch Clinical Trials
214
mi
from
Saint Joseph, MO
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
MediSearch Clinical Trials
214
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
St. Louis Hospital
415
mi
from
Saint Louis, MO
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
St. Louis Hospital
415
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
University of Alabama at Birmingham Cancer Center
684
mi
from
Birmingham, AL
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
University of Alabama at Birmingham Cancer Center
684
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Alaska Breast Care and Surgery LLC
2732
mi
from
Anchorage, AK
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Alaska Breast Care and Surgery LLC
2732
mi
from
Anchorage, AK
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Alaska Women's Cancer Care
2732
mi
from
Anchorage, AK
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Alaska Women's Cancer Care
2732
mi
from
Anchorage, AK
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Anchorage Oncology Centre
2732
mi
from
Anchorage, AK
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Anchorage Oncology Centre
2732
mi
from
Anchorage, AK
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Katmai Oncology Group
2732
mi
from
Anchorage, AK
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Katmai Oncology Group
2732
mi
from
Anchorage, AK
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Providence Alaska Medical Center
2732
mi
from
Anchorage, AK
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Providence Alaska Medical Center
2732
mi
from
Anchorage, AK
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Beebe Medical Center
1229
mi
from
Lewes, DE
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Beebe Medical Center
1229
mi
from
Lewes, DE
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Christiana Gynecologic Oncology LLC
1194
mi
from
Newark, DE
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Christiana Gynecologic Oncology LLC
1194
mi
from
Newark, DE
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Delaware Clinical & Laboratory Physicians, PA
1193
mi
from
Newark, DE
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Delaware Clinical & Laboratory Physicians, PA
1193
mi
from
Newark, DE
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Helen F. Graham Cancer Center
1195
mi
from
Newark, DE
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Helen F. Graham Cancer Center
1195
mi
from
Newark, DE
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Medical Oncology Hematology Consultants
1193
mi
from
Newark, DE
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Medical Oncology Hematology Consultants
1193
mi
from
Newark, DE
Click here to add this to my saved trials